Showing 2231-2240 of 3039 results for "".
- OKYO Pharma Secures Funding to Advance Urcosimod for Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-secures-funding-to-advance-urcosimod-for-neuropathic-corneal-pain/2482926/OKYO Pharma announced it has received $1.9 million in non-dilutive funding to accelerate the clinical development of urcosimod, the company’s lead candidate for treating Neuropathic Corneal Pain (NCP) “Neur
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)
- Alcon to Acquire Staar Surgical for $1.5 Billionhttps://modernod.com/news/alcon-to-acquire-staar-surgical-for-15-billion/2482917/In a major deal to expand its refractive portfolio and continue its spree of acquisitions, Alcon has agreed to acquire Staar Surgical, maker of the Implantable Collamer Lens (ICL). The acquisition includes the EVO family of l
- Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatmenthttps://modernod.com/news/genentech-unveils-five-year-data-for-susvimo-long-term-efficacy-and-durability-in-wet-amd-treatment/2482915/Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The fin
- EyePoint Completes Enrollment of Phase 3 Trials for Duravyu in Wet AMDhttps://modernod.com/news/eyepoint-completes-enrollment-of-phase-3-trials-for-duravyu-in-wet-amd/2482907/EyePoint Pharmaceuticals has completed enrollment of its phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal noninferiority trials evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD). The first p
- Ziemer USA Announces New Innovations for the Galilei Diagnostic Platform and FEMTO LDV Z8 Femtosecond Laserhttps://modernod.com/news/ziemer-usa-announces-new-innovations-for-the-galilei-diagnostic-platform-and-femto-ldv-z8-femtosecond-laser-platform/2482904/Ziemer USA, in partnership with CorneaGen, announced the launch of the Galilei CTAK module, which is now available for use with the Galilei diagnostic platform. "We are thrilled to complete our product offering for CTAK patients. With the addition of the Galilei CTAK module in combination
- AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into Phase 1/2 Clinical Trialhttps://modernod.com/news/aavantgarde-receives-fda-clearance-to-progress-stargardt-disease-asset-aavb-039-into-phase-12-clinical-trial/2482885/AAVantgarde Bio announced that the FDA has cleared its investigational new drug (IND) application for AAVB-039, the company’s gene therapy program for Stargardt disease. AAVantgarde is now initiating CELESTE, a first-in-human phase 1/2 clinical trial in the United States to e
- The Vision Council Comments on Impact of Proposed Tariffs on Optical Industryhttps://modernod.com/news/the-vision-council-comments-on-impact-of-proposed-tariffs-on-optical-industry/2482880/The Vision Council has released a letter summarizing the recent tariffs proposed by the Trump administration and the impact it could have on the optical industry. The White House issued formal notice to several US trading partners outlining tariff
- Beacon Therapeutics Completes Enrollment in Registrational Phase 2/3 VISTA Trial of laru-zova for Patients with XLRPhttps://modernod.com/news/beacon-therapeutics-completes-enrollment-in-registrational-phase-23-vista-trial-of-laru-zova-for-patients-with-xlrp-1/2482875/Beacon Therapeutics announced it has completed enrollment in its registrational phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP). The study enrolled eligible male patients aged 12 to 50 across sites in North America, the United Kingdom
- First Patient Dosed in the Phase 1 Trial of PulseSight Therapeutics’ Investigational PST-611 Treatment for Dry AMD/GAhttps://modernod.com/news/first-patient-dosed-in-the-phase-1-trial-of-pulsesight-therapeutics-investigational-pst-611-treatment-for-dry-amdga/2482874/PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial (PST-611-CT1) assessing the safety and tolerability of its lead program, PST-611, in humans. PST-611 is a first-in-class non-viral vectorized